INTRODUCTION
Bile acids such as lithocholic acid (LCA) and ursodeoxycholic acid (UDCA) (Scheme 1) have been considered quite useful as starting points for a rich and different set of medicinal chemistry activities. [1] The literature describes a large amount of pharmacological applications for bile acids derivatives, in particular antimicrobial, antifungal and antitumor. Besides, the discovery of bioactive ingredients from plants and fungi is always the main target in medicinal chemistry. The lanostanetype triterpenoid 3β-hydroxylanosta-8,24-diene-21-oic acid (Trametenolic acid, TMA) (Scheme 2) was the main bioactive component of Gloeophyllum odoratum [2] , which was reported to possess widely bioactivities, including tumor cell anti-proliferation effects (for example, human HL-60 leukemia, human KB epidermoid carcinoma, murine L1210 leukemia cells, Caski, HT-3, T-24, etc.), inhibition of enzyme activity (human thrombin, bovine trypsin and so on). Nevertheless, trametenolic acid was scarcely investigated as antimicrobial agent. A new series of lithocholic, ursodeoxycholic and lanostane acid derivatives were synthesized through modification at the oxygenated carbon C-3 and/or C-7 and at the carboxyl carbon C-24 or C-21. 
RESULTS
The aim of the present study is to obtain a new series of derivatives bearing a guanidine moiety in their side chain through modification at the carboxyl carbon C-24 or C-21 and an acetoxy group at the oxygenated carbon C-3 and/or C-7.
The activity of bile acids, trametenolic acid and derivatives was evaluated against the growth of S. aureus, B. subtilis and M. smegmatis. The derivative 3α-hydroxy-23-guanidino-5β-cholane (6) showed the best activity, with MIC values of 12.5 µM against S. aureus, 5 µM against B. subtilis and 50 µM against M. smegmatis. The cytotoxic activity of bile acids, trametenolic acid and derivatives was also evaluated against HT-29 cell line.
IN VITRO STUDY

SYNTHESIS OF CHOLANE AND LANOSTANE DERIVATIVES
Scheme 1: Reagents and conditions: (a) Ac 2 O/pyridine, DMAP, rt, 24 h, 96% (2), 78% (2a); (b) NEt 3 , DPPA, Toluene, 150°C, reflux, 3h; (c) NaOTMS/THF 1M, 0°C, 1h, 64% (3), 66% (3a); (d) NEt 3 , AgNO 3 /CH 2 Cl 2 , N,N'-Di-Boc-S-methylisothiourea, 40% (4), 41% (4a); (e) TFA/CH 2 Cl 2 , 86% (5), 89% (5a); (f) NaOH/MeOH, 150°C, 1h; (g) TFA/CH 2 Cl 2 , 82% (6), 76% (6a) . Scheme 2:Reagents and conditions: (a) Ac 2 O/pyridine, DMAP, rt, 24 h, 87%; (b) NEt 3 , DPPA, Toluene, 150ºC, reflux, 3h; (c) NaOTMS/THF 1M, 0°C, 1h, 67%; (d) NEt 3 , AgNO 3 /CH 2 Cl 2 , N,N'-Di-Boc-S-methylisothiourea, 44%; (e) TFA/CH 2 Cl 2, 87%; (f) NaOH/MeOH, 150°C, 1h; (g) TFA/CH 2 Cl 2 , 87% . 
